Lyser-AP Tablet is a combination analgesic formulation containing Aceclofenac 100mg, Paracetamol 325mg, and Serratiopeptidase 15mg, designed for the effective management of pain and inflammation. Aceclofenac, a non-steroidal anti-inflammatory drug (NSAID), exerts its therapeutic effect by inhibiting cyclooxygenase enzymes, thereby reducing prostaglandin synthesis responsible for inflammation and pain. Paracetamol, a widely used analgesic and antipyretic agent, complements Aceclofenac by providing additional pain relief and fever reduction through central inhibition of prostaglandin synthesis. Serratiopeptidase, a proteolytic enzyme, facilitates the breakdown of inflammatory mediators and promotes the resolution of edema and tissue inflammation. This synergistic combination is indicated for the treatment of musculoskeletal disorders such as osteoarthritis, rheumatoid arthritis, postoperative pain, and soft tissue injuries. Lyser-AP Tablet should be administered as per the prescribing physician’s guidance, considering patient-specific factors including medical history and concomitant medications. Caution is advised in patients with gastrointestinal ulcers, hepatic or renal impairment, and hypersensitivity to NSAIDs. Regular monitoring may be necessary during prolonged therapy. Overall, Lyser-AP Tablet offers a balanced approach to pain management by targeting multiple pathways involved in inflammation and analgesia.